It has been proposed that in patients with WWOX↑ POLE4↑ HSF2BP↑ expression profile (who account for ~6–7% of the entire cohort), WWOX protein may not be available for its cooperating partners, which is manifested by the absence of anti-cancer activity despite a high WWOX level. This evidence concerns the gene WWOX and cancer.